Click here to close now.




















Welcome!

News Feed Item

Imprimis Pharmaceuticals' Pre-Commercial Ophthalmic Formulations to be Presented at 2014 American-European Congress of Ophthalmic Surgery (ACOS™)/Dulaney Winter Meeting

--First-time cataract formulation clinical data and clinical experience will be presented at a U.S. ophthalmic meeting --

SAN DIEGO, Feb. 25, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that James Lewis, MD (http://cataractphiladelphia.com), will present "Dropless Cataract Surgery" during the New Technologies Session of the American-European Congress of Ophthalmic Surgery (ACOS™). The society's Winter Meeting is being held February 23-26, 2014, in Aspen, Colorado. This will be the first time clinical data and clinical experience with Imprimis' dropless cataract surgery formulations and related administration techniques will be presented at a U.S. clinical meeting. ACOS (http://acosurgery.org) represents and educates surgeons, innovators, and industry leaders who have made a significant contribution to the field of ophthalmology.

The Imprimis Pharmaceuticals proprietary ophthalmic therapies that Dr. Lewis will showcase during his presentation were prescribed by Dr. Lewis for more than 400 cataract surgery patients, and include a formulation combining triamcinolone acetonide, moxifloxacin hydrochloride and the antibiotic vancomycin. A second formulation is available with triamcinolone acetonide and moxifloxacin hydrochloride. Both of these proprietary formulations have been used by select physicians during thousands of cataract surgeries and many other eye surgeries where, as a result of the surgery, there is inflammation and a chance for post-operative infection. Dr. Lewis's presentation will include video in which he demonstrates a transzonular approach for the injection of the drugs intraoperatively. He will also examine the benefits of dropless cataract surgery for both doctors and patients. Dr. Lewis is not an employee or consultant of Imprimis.

This presentation by Dr. Lewis builds on Imprimis' strong momentum from participation at previous meetings, including the American Academy of Ophthalmology in New Orleans, La., the "Cataract Surgery: Telling It Like It is" meeting in Sarasota, Fla., and the Caribbean Eye Meeting in Cancun, Mexico. In addition to its presence at these meetings, the company has held several Ophthalmic Advisory Board meetings with national thought leaders.  Each of these events provides the opportunity to build relationships and gain valuable insight on the company's innovations and business model from the perspective of the ophthalmic surgeons who participate.

Imprimis previously announced plans to make available its proprietary ophthalmic compounded therapies during the first half of 2014, and is continuing its Go Dropless™ campaign (http://GoDropless.com/). The campaign was created to inform ophthalmologists about dropless ophthalmic surgery opportunities and the unique injectable compounded drug formulations Imprimis has developed in conjunction with physicians and pharmacists.

ABOUT DROPLESS OPHTHALMIC SURGERY FORMULATIONS
Imprimis acquired the intellectual property for these patent-pending formulations in August of 2013. As the company stated at that time, the current treatment regimen for the prevention of post-cataract surgery complications is a costly pre-operative and post-operative patient-administered eye drop regimen, which requires strict patient compliance and careful adherence to a prescribed dosing schedule. Individuals with physical limitations, impaired manual dexterity, or those who lack a supportive caregiver, are particularly vulnerable to non-compliance and the subsequent complications of untreated post-surgical issues. Imprimis' unique drug formulations utilize a fourth generation quinolone therapy combined with anti-inflammatory agent, providing new choices for physicians to address the primary ocular complications of ophthalmic surgery - risk of infection and post-operative inflammation.

Imprimis believes that its proprietary formulations may have a broad application in ophthalmic surgery, including the multi-billion global cataract surgery drug market where the company believes there is an opportunity for technological advancement to meet patient interest to reduce or eliminate the need for post-surgery eye drops. The cataract surgery market continues exponential growth. Nearly 22 million cataract surgeries were performed globally in 2013, according to Market Scope.1 This growth is not only due to the expanding aging population, but because the age at which patients demand cataract surgery has lowered, shown in a study by Mayo Clinic2, portending the ophthalmology drug market to reach an estimated $21.6 billion by 20183.

ABOUT IMPRIMIS PHARMACEUTICALS
San Diego-based Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY) is a specialty pharmaceutical company focused on the development and commercialization of proprietary and novel sterile and topical drug formulations. Certain of Imprimis' patent-pending drug formulations are available today and are being prescribed by physicians.  For more information, please visit www.imprimispharma.com or www.GoDropless.com.

SAFE HARBOR
This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include risks and uncertainties related to Imprimis' ability to make available its formulations during the expected timeframe or at all; physician interest in prescribing its formulations, Imprimis' ability to close the acquisition of Pharmacy Creations, LLC and realize the expected benefits of the transaction and enter , into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of its formulations; its ability to commercialize its formulations and technologies, obtain intellectual property protection for its assets, its ability to accurately estimate its expenses and cash burn, and raise additional funds when necessary, risks related to research and development activities;, the projected size of the potential market for its technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at www.sec.gov. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

MEDIA CONTACT:  Jen Carroll
[email protected]
858.704.4587

SOURCE Imprimis Pharmaceuticals, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
"Alert Logic is a managed security service provider that basically deploys technologies, but we support those technologies with the people and process behind it," stated Stephen Coty, Chief Security Evangelist at Alert Logic, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
"We specialize in testing. DevOps is all about continuous delivery and accelerating the delivery pipeline and there is no continuous delivery without testing," noted Marc Hornbeek, Sr. Solutions Architect at Spirent Communications, in this SYS-CON.tv interview at @DevOpsSummit, held June 9-11, 2015, at the Javits Center in New York City.
"ProfitBricks was founded in 2010 and we are the painless cloud - and we are also the Infrastructure as a Service 2.0 company," noted Achim Weiss, Chief Executive Officer and Co-Founder of ProfitBricks, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
With SaaS use rampant across organizations, how can IT departments track company data and maintain security? More and more departments are commissioning their own solutions and bypassing IT. A cloud environment is amorphous and powerful, allowing you to set up solutions for all of your user needs: document sharing and collaboration, mobile access, e-mail, even industry-specific applications. In his session at 16th Cloud Expo, Shawn Mills, President and a founder of Green House Data, discussed h...
"We do data integration for B2B also application to application, and we do data management and enable Big Data," explained Pat Adamiak, Vice President, Product Marketing at Liaison Technologies, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
The Cloud industry has moved from being more than just being able to provide infrastructure and management services on the Cloud. Enter a new era of Cloud computing where monetization’s services through the Cloud are an essential piece of strategy to feed your organizations bottom-line, your revenue and Profitability. In their session at 16th Cloud Expo, Ermanno Bonifazi, CEO & Founder of Solgenia, and Ian Khan, Global Strategic Positioning & Brand Manager at Solgenia, discussed how to easily o...
One of the hottest areas in cloud right now is DRaaS and related offerings. In his session at 16th Cloud Expo, Dale Levesque, Disaster Recovery Product Manager with Windstream's Cloud and Data Center Marketing team, will discuss the benefits of the cloud model, which far outweigh the traditional approach, and how enterprises need to ensure that their needs are properly being met.
Palerra, the cloud security automation company, announced enhanced support for Amazon AWS, allowing IT security and DevOps teams to automate activity and configuration monitoring, anomaly detection, and orchestrated remediation, thereby meeting compliance mandates within complex infrastructure deployments. "Monitoring and threat detection for AWS is a non-trivial task. While Amazon's flexible environment facilitates successful DevOps implementations, it adds another layer, which can become a ...
The speed of software changes in growing and large scale rapid-paced DevOps environments presents a challenge for continuous testing. Many organizations struggle to get this right. Practices that work for small scale continuous testing may not be sufficient as the requirements grow. In his session at DevOps Summit, Marc Hornbeek, Sr. Solutions Architect of DevOps continuous test solutions at Spirent Communications, explained the best practices of continuous testing at high scale, which is rele...
"We got started as search consultants. On the services side of the business we have help organizations save time and save money when they hit issues that everyone more or less hits when their data grows," noted Otis Gospodnetić, Founder of Sematext, in this SYS-CON.tv interview at @DevOpsSummit, held June 9-11, 2015, at the Javits Center in New York City.
Growth hacking is common for startups to make unheard-of progress in building their business. Career Hacks can help Geek Girls and those who support them (yes, that's you too, Dad!) to excel in this typically male-dominated world. Get ready to learn the facts: Is there a bias against women in the tech / developer communities? Why are women 50% of the workforce, but hold only 24% of the STEM or IT positions? Some beginnings of what to do about it! In her Opening Keynote at 16th Cloud Expo, S...
Delphix, the market leader in Data as a Service (DaaS), has been announced winner of the DevOps Solution Award at the prestigious Computing Vendor Excellence Awards in London. The awards celebrate the achievements of the technology vendors and service providers that are leading the field of enterprise IT. Delphix was recognised as the vendor demonstrating the most effective support of DevOps culture for its ability to improve time to market and collaboration between teams.
"Our biggest growth area has been the security services, the managed services - the things that differentiate us in the market that there is no client that's too small and there's no client that's too big," explained Paul Mazzucco, Chief Security Officer at TierPoint, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
"We've just seen a huge influx of new partners coming into our ecosystem, and partners building unique offerings on top of our API set," explained Seth Bostock, Chief Executive Officer at IndependenceIT, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
Explosive growth in connected devices. Enormous amounts of data for collection and analysis. Critical use of data for split-second decision making and actionable information. All three are factors in making the Internet of Things a reality. Yet, any one factor would have an IT organization pondering its infrastructure strategy. How should your organization enhance its IT framework to enable an Internet of Things implementation? In his session at @ThingsExpo, James Kirkland, Red Hat's Chief Arch...